Apremilast improves skin outcomes in pediatric plaque psoriasis of shorter disease duration: 52-week results from the SPROUT phase 3 trial

Langley RG, Arkin L, Fiorillo L, Eichenfield LF, Lebwohl M, Strober B, Sticherling M, Swanson L, Kokolakis G, Chaudhari S, Deignan C, Zhang Z, Paller AS (2026)

Publication Type: Journal article

Publication year: 2026

Journal

Journal of the American Academy of Dermatology Elsevier

DOI: 10.1016/j.jaad.2026.01.072

Authors with CRIS profile

Michael Sticherling Department of Dermatology

Involved external institutions

Dalhousie University

Canada (CA) University of Wisconsin - Madison

United States (USA) (US) University of Alberta

Canada (CA) University of California, San Diego (UC San Diego, UCSD)

United States (USA) (US) Cardiovascular Research Foundation

United States (USA) (US) Yale University

United States (USA) (US) Charité - Universitätsmedizin Berlin

Germany (DE) Amgen Inc.

United States (USA) (US) Northwestern University

United States (USA) (US)

How to cite

APA:

Langley, R.G., Arkin, L., Fiorillo, L., Eichenfield, L.F., Lebwohl, M., Strober, B.,... Paller, A.S. (2026). Apremilast improves skin outcomes in pediatric plaque psoriasis of shorter disease duration: 52-week results from the SPROUT phase 3 trial. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.01.072

MLA:

Langley, Richard G., et al. "Apremilast improves skin outcomes in pediatric plaque psoriasis of shorter disease duration: 52-week results from the SPROUT phase 3 trial." Journal of the American Academy of Dermatology (2026).

BibTeX: Download